HEALTH● LOWAug 5 · Aug 5, 2026, 4:31 PM
United Therapeutics anticipates potential 2027 approvals for ralinepag and Tyvaso IPF while holding 2026 revenue outlook unchanged
Seeking Alpha Tech
United Therapeutics expects potential 2027 approvals for ralinepag and Tyvaso IPF while maintaining its 2026 revenue outlook. This provides an update on the company's product pipeline and financial projections.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH24m agoInside Bunia’s fight to protect families from DRC’s deadliest Ebola outbreakRFI [en]HEALTH27m agoRoutine testosterone screening of US troops may require extensive follow-on care, study findsMilitary TimesHEALTH27m agoRoutine testosterone screening of US troops may require extensive follow-on care, study findsDefense NewsHEALTH28m agoKeralam considering sites in Thrissur, Kasaragod for proposed All-India Institute of AyurvedaThe Hindu